AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 7 - (NewsRx.com & NewsRx.net) -- The American College of Obstetricians and Gynecologists (ACOG) has issued new recommendations on the use of selective estrogen receptor modulators (SERMS), which are a relatively new class of synthetic estrogens that act like estrogen in certain parts of the body (such as the bones) while leaving other parts of the body unaffected.
The use of SERMS as alternative treatment to hormone replacement therapy in postmenopausal women has received increased public attention in the wake of the recent Women's Health Study results, which revealed small but significant increased risks for certain diseases in women using hormone replacement therapy.
Although SERMS are referred to collectively, their effects on different parts of the body can vary. ACOG's new practice bulletin focuses on the use of SERMS in women for their FDA-approved uses - particularly tamoxifen for reduction of breast cancer risk, and raloxifene for protection against osteoporosis.
ACOG noted that tamoxifen, originally developed to treat breast cancer patients, can be considered as a therapy to help ...